AngioDynamics (ANGO) announced enrollment of the first patient in the randomized study of the Auryon Atherectomy System Used in Combination with Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone Treating Infrapopliteal Lesions in Subjects with Critical Limb Ischemia Below-the-Knee.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANGO:
- AngioDynamics meets primary endpoint in PRESERVE study
- AngioDynamics’ Strong FY25 Performance and Optimistic FY26 Outlook Support Buy Rating
- AngioDynamics initiated with a Buy at Lake Street
- AngioDynamics price target raised to $17 from $15 at Canaccord
- AngioDynamics Reports Strong Growth in Fiscal 2025